You might have seen in the news: this week, the FDA approved the first generic version of capecitabine (Xeloda to most of us), an oral chemotherapy pill used to treat breast and colon cancers.
So what does this mean? Basically, when generic versions of drugs become available to the masses, it can mean better access for patients. We all know – brand-name drugs can be VERY pricey, sometimes so much so that people who need the drug can’t even afford it. The good news: typically, generic forms of drugs cost significantly less than the brand-name equivalents and still provide the same effectiveness.
So in this case, patients who had been receiving the brand-name version of Xeloda will be spending less for the same treatment and patients who couldn’t afford the medication can now ask their doctors if the generic version is right for them.
Different Drug, Same Quality
If you’re worried about the quality of these new, non-name-brand forms of Xeloda, don’t be. Remember that all FDA-approved generic drugs are subject to the same stringent guidelines and are held to the same standards as their brand-name equivalent. Actually, as cancer continues to be treated as a chronic illness, we will likely be seeing other generic versions of popular treatments become available. A generic drug may look or taste different or even have different inactive ingredients, but in general, it shouldn’t be any less effective for you.
Ow, Ow! Choose Me! Over Here!
So then why are generic drugs SO much cheaper? Because the companies that offer these drugs didn’t have to spend the money to research, develop and market them (and as you can imagine – this process this isn’t a cheap one.) Another reason: more forms of a drug on the market means increased competition; companies are forced to keep their prices lower so that people will actually buy their product.
There you have it! If you have questions, call our Toll-free Helpline at (877) 422-2030. Find more information here.
Top resources
Krazati approved for previously treated KRASG12C colorectal cancer
The treatment option is for patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC) who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Top five things to know about choosing sedation for your colonoscopy
You have a choice when it comes to colonoscopy sedation, and we’re here to help make that decision easier.
Christy Williams: Biomarker testing leads to successful treatment
Statistics suggested that Christy’s odds of survival were grim, so she leaned into her faith and kept a positive outlook. She tried to control what she could. And, critically, she received biomarker testing.